LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Kitov Pharmaceutical Holdings Ltd. ("Kitov" or the "Company") (Nasdaq: KTOV). Investors who purchased or otherwise acquired Kitov shares between November 20, 2015 and February 3, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 10, 2017 lead plaintiff deadline.
No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
On February 6, 2017, the Israeli publication Calcalist announced that Kitov’s Chief Executive Officer, Isaac Israel, had been held by the Israeli Securities Authority in response to allegations of publishing misleading information about a recent clinical trial of one of Kitov’s products. When this information was disclosed to the investing public, the value of Kitov stock fell, causing investors serious harm.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.